WithdrawnPhase 2

Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination

Stopped: No candidates for the trial (all patients have received the third dose of the vaccine)

0Started 2021-09

Plain-language summary

The objective will be to analyze the development of cellular and humoral immunity against SARS-CoV-2 after administration of a third dose of mRNA-1273 (Moderna) vaccine in patients who have remained seronegative after the full standard (two-dose) regimen.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age \> 18 years;
✓. Male or female sex;
✓. Renal transplant with stable renal function in the last 2 months prior to study inclusion.
✓. Had received a full schedule of vaccination for SARS-CoV-2 with mRNA1273 vaccine (Moderna) and remained seronegative at 2 weeks after the second dose.
✓. Patient giving written informed consent.

Exclusion criteria

✕. Renal transplantation \< 3 months;
✕. Pregnancy or lactation status;
✕. Rejection treated within the last 6 months;
✕. Presence of humoral immunity to SARS-CoV-2 defined as the presence of specific IgM/IgG.

What they're measuring

Number of patients with development of cellular and humoral immunity against SARS-CoV-2

Timeframe: 2 weeks

Trial details

NCT IDNCT04930770

SponsorMaria Joyera Rodríguez

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-12-01

View on ClinicalTrials.gov More Covid19 trials